Email Alert | RSS

北京大学学报（医学版） ›› 2021, Vol. 53 ›› Issue (4): 721-727. doi: 10.19723/j.issn.1671-167X.2021.04.017

• 论著 • 上一篇    下一篇

外周血淋巴细胞亚群检测在系统性硬化症治疗中的应用

马向波1,2,张学武1,贾汝琳1,高颖3,刘洪江1,刘玉芳1,4,李英妮1,Δ()   

  1. 1.北京大学人民医院风湿免疫科, 北京 100044
    2.邯郸市第一医院风湿免疫科, 河北邯郸 056002
    3.北京大学人民医院内分泌科, 北京 100044
    4.山西医科大学第二医院风湿免疫科, 太原 030000
  • 收稿日期:2020-07-26 出版日期:2021-08-18 发布日期:2021-08-25
  • 通讯作者: 李英妮 E-mail:ying8436@aliyun.com
  • 基金资助:
    国家自然科学基金(81701614);北京大学人民医院研究与发展基金(RDC2019-01)

Application of lymphocytes test in peripheral blood of patients with systemic sclerosis during the treatment

MA Xiang-bo1,2,ZHANG Xue-wu1,JIA Ru-lin1,GAO Ying3,LIU Hong-jiang1,LIU Yu-fang1,4,LI Ying-ni1,Δ()   

  1. 1. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing 100044, China
    2. Department of Rheumatology and Immunology, Handan First Hospital, Handan 056002, Hebei, China
    3. Department of Endocrinology, Peking University People’s Hospital, Beijing 100044, China
    4. Department of Rheumatology and Immunology, Second Hospital of Shanxi Medical University,Taiyuan 030000, China
  • Received:2020-07-26 Online:2021-08-18 Published:2021-08-25
  • Contact: Ying-ni LI E-mail:ying8436@aliyun.com
  • Supported by:
    National Natural Science Foundation of China(81701614);Peking Univercity People’s Hospital Research and Development Funds(RDC2019-01)

RICH HTML

 10   

PDF (PC)

208

摘要：

目的: 检测免疫抑制剂治疗中系统性硬化症 (systemic sclerosis, SSc) 患者外周血T淋巴细胞、B淋巴细胞及自然杀伤 (natural killer,NK) 细胞的表达水平,分析其与临床实验室指标之间的相关性,进而探讨外周血淋巴细胞亚群检测在SSc治疗中的意义。方法: 采用流式细胞术检测使用免疫抑制剂的32例SSc患者(SSc组)和 30例健康对照(healthy control,HC)组外周血T、CD4+T、CD8+T、B、NK细胞数量及比例,比较SSc组与HC组外周血淋巴细胞亚群的差异,分析外周血淋巴细胞亚群与SSc其他实验室及临床指标之间的相关性。结果: 与HC组相比,SSc组中T、CD4+T、CD8+T、B、NK细胞数量均明显减少 (P<0.05), 同时,NK细胞占淋巴细胞的百分比也明显降低(P=0.004); 此外,使用免疫抑制剂的SSc患者中65%以上外周血存在各淋巴细胞亚群细胞数量减少。CD4+T淋巴细胞数量降低组与正常组相比,其出现雷诺现象的比例明显升高(P=0.024), 红细胞沉降率和C-反应蛋白也明显升高(P<0.001,P=0.018); CD8+T淋巴细胞数量降低组与正常组相比,红细胞沉降率明显升高(P=0.022);B淋巴细胞数量降低组与正常组相比,发生指尖溃疡的风险明显增高(P=0.019); NK细胞数量降低组与正常组相比,发生指尖溃疡的风险明显增高(P=0.033),而体内免疫球蛋白(immunoglobulin,Ig)M水平明显降低(P=0.049)。相关性分析可见,红细胞沉降率与总T淋巴细胞(r=-0.455,P=0.009)、CD4+T淋巴细胞(r=-0.416,P=0.018)、CD8+T淋巴细胞(r=-0.430,P=0.014)、B细胞(r=-0.366,P=0.039)数量呈负相关。结论: +T、CD8+T、B及NK细胞数量明显减少,某些淋巴细胞亚群的变化可能与雷诺现象、指尖溃疡的发生有关,与红细胞沉降率、C-反应蛋白呈明显负相关,使用免疫抑制剂治疗SSc中应定期检测外周血淋巴细胞亚群的细胞数量。

关键词: 系统性硬化症, T淋巴细胞, B淋巴细胞, 自然杀伤细胞

Abstract:

Objective: To explore the significance of lymphocytes in systemic sclerosis (SSc), by detecting the levels of T lymphocytes, B lymphocytes and natural killer (NK) cells, and analyzing the correlation between the lymphocytes and clinical laboratory indexes. Methods: The numbers and proportion of T, CD4+T, CD8+T, B, and NK cells were detected by flow cytometry in peripheral blood of 32 SSc patients who had taken immunosuppressive drugs and 30 healthy controls (HC). The comparison of the lymphocyte subsets in SSc with them in the HC groups, and the correlation between the lymphocytes and other clinical and laboratory indicators were analyzed by the relevant statistical analysis. Results: Compared with the HC group, the numbers of T, CD4+T, CD8+T, and NK cells in peripheral blood of SSc group,who had taken immunosuppressive drugs, were significantly decreased (P<0.05). More-over, the proportion of NK cells in peripheral blood of the SSc group was also significantly lower than that in the HC group (P=0.004). In addition, all the lymphocyte subsets were decreased in peripheral blood of more than 65% of the SSc patients who had taken immunosuppressive drugs. Compared with CD4+T normal group, the positivity of Raynaud’s phenomenon, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) was significantly increased in CD4+T reduction group, respectively (P=0.024, P<0.001, P=0.018). ESR was higher in CD8+T reduction group than CD8+T normal group (P=0.022). The prevalence of fingertip ulcer was significantly increased in B cell decrease group (P=0.019). Compared with NK cell normal group, the prevalence of fingertip ulcer was significantly increased in NK cell lower group (P=0.033), IgM was remarkablely decreased yet (P=0.049). The correlation analysis showed that ESR was negatively correlated with the counts of T lymphocytes (r=-0.455, P=0.009), CD4+T lymphocytes (r=-0.416, P=0.018), CD8+T lymphocytes (r=-0.430, P=0.014), B cells (r=-0.366, P=0.039). Conclusion: The number of CD4+T, CD8+T, B, and NK cells significantly decreased in peripheral blood of SSc patients who had used immunosuppressive drugs, some lymphocyte subsets might be related with Raynaud’s phenomenon and fingertip ulcer, and reflected the disease activity by negatively correlated with ESR and CRP; the numbers of lymphocyte subsets in peripheral blood should be detected regularly in SSc patients who had taken immunosuppressive drugs.

Key words: Systemic sclerosis, T lymphocytes, B lymphocytes, Natural killer cells

中图分类号: 

  • R593.25

表1

SSc患者与正常对照组外周血T淋巴细胞亚群、B细胞及NK细胞的比较"

Group Number of lymphocytes/(×106/L)
T cells CD4+T cells CD8+T cells B cells NK cells
HC 1 539(1 296-1704) 835(678-926) 566(477-721) 228(169-293) 262(216-336)
SSc 1 010(554-1368) 639(355-803) 347(205-529) 141(73-262) 143(59-179)
P <0.001 0.017 0.001 0.022 <0.001

表2

SSc患者与HC组外周血T淋巴细胞亚群、B细胞及NK细胞的百分比"

Group Percentage of cells/%
T cells CD4+T cells CD8+T cells B cells NK cells
HC 73.61±6.36 41.41±7.28 29.65±6.28 11.29±3.83 14.27±4.79
SSc 76.62±10.14 48.05±11.35 28.80±9.60 12.16±6.88 10.02±5.43
P 0.099 0.017 0.260 0.573 0.004

表3

CD4+T淋巴细胞与临床实验室指标之间的关系"

Items Reduction group (n=14) Normal group (n=18) P
Age/years, $\bar{x}±s$ 51.64±14.56 49.72±13.17 0.699
Women, n(%) 13 (92.86) 18 (100) 1.000
Disease duration/years, M(P25, P75) 8.50 (1, 28) 3.75 (0.5, 20) 0.085
Raynaud’s phenomenon, n(%) 14 (100) 12 (66.67) 0.024
Diffuse cutaneous changes, n(%) 13 (92.86) 12 (66.67) 0.104
Fingertip ulcer, n(%) 3 (21.43) 4 (22.22) 1.000
Pulmonary interstitial fibrosis, n(%) 12 (83.71) 11 (61.11) 0.235
ANA, n(%) 13 (92.86) 16 (88.89) 1.000
Scl-70, n(%) 5 (35.71) 6 (33.33) 1.000
ESR/(mm/h), M(P25, P75) 25 (18.00, 41.50) 9.00 (7.50, 14.50) <0.001
CRP/(mg/L), M(P25, P75) 7.93 (1.76, 14.72) 2.21 (0.47, 3.14) 0.018
IgG/(g/L), M(P25, P75) 14.25 (10.20, 19.70) 11.05 (9.65, 15.40) 0.180
IgM/(g/L), M(P25, P75) 0.81 (0.64, 1.05) 0.85 (0.66, 1.04) 0.955
IgA/(g/L), $\bar{x}±s$ 2.11±1.28 2.24±1.49 0.798
C3/(g/L), $\bar{x}±s$ 0.85±0.24 0.89±0.17 0.583
C4/(g/L), $\bar{x}±s$ 0.19±0.08 0.19±0.07 0.979

表4

CD8+T淋巴细胞与临床实验室指标之间的关系"

Reduction group (n=15) Normal group (n=17) P
Age/years, $\bar{x}±s$ 47.76±13.79 53.73±13.10 0.221
Women, n(%) 15 (100) 16 (94.12) 0.531
Disease duration/years, M(P25, P75) 4 (0.5, 20) 6.5 (1, 28) 0.189
Raynaud’s phenomenon, n(%) 12 (70.59) 14 (93.33) 0.178
Diffuse cutaneous changes, n(%) 13 (76.47) 12 (80) 0.355
fingertip ulcer, n(%) 3 (17.65) 4 (26.66) 0.678
Pulmonary interstitial fibrosis, n(%) 12 (70.59) 11 (73.33) 1.000
ANA, n(%) 14 (93.33) 15 (88.24) 1.000
Scl-70, n(%) 5 (33.33) 6 (35.29) 1.000
ESR/(mm/h), M(P25, P75) 23.00 (11.50, 27.50) 9.00 (7.50, 17.00) 0.022
CRP/(mg/L), M(P25, P75) 7.15 (0.71, 12.83) 2.43 (0.55, 3.14) 0.142
IgG/(g/L), M(P25, P75) 13.50 (9.30, 16.40) 11.20 (9.50, 15.70) 0.551
IgM/(g/L), M(P25, P75) 0.77 (0.52, 0.94) 0.91 (0.72, 1.18) 0.370
IgA/(g/L), $\bar{x}±s$ 1.96±1.27 2.39±1.48 0.387
C3/(g/L), $\bar{x}±s$ 0.87±0.20 0.88±0.21 0.940
C4/(g/L), $\bar{x}±s$ 0.20±0.07 0.18±0.08 0.520

表5

B细胞与临床实验室指标之间的关系"

Reduction group (n=10) Normal group (n=22) P
Age/years, $\bar{x}±s$ 56.00±12.61 48.09±13.57 0.129
Women, n(%) 10 (100) 21 (95.45) 1.000
Disease duration/years, M(P25, P75) 10.5 (1, 28) 4 (0.5, 20) 0.052
Raynaud’s phenomenon, n(%) 10 (100) 16 (72.73) 0.142
Diffuse cutaneous changes, n(%) 10 (100) 15 (68.18) 0.069
fingertip ulcer, n(%) 5 (50) 2 (9.09) 0.019
Pulmonary interstitial fibrosis, n(%) 8 (80) 15 (68.18) 0.681
ANA, n(%) 8 (80.00) 21 (95.45) 0.224
Scl-70, n(%) 4 (40.00) 7 (31.82) 0.703
ESR/(mm/h), M(P25, P75) 21.00 (10.00, 26.00) 10.50 (7.50, 20.00) 0.092
CRP/(mg/L), M(P25, P75) 6.78 (0.97, 9.9) 2.50 (0.55, 5.19) 0.325
IgG/(g/L), M(P25, P75) 12.25 (10.15, 14.4) 11.70 (9.50, 15.70) 0.889
IgM/(g/L), M(P25, P75) 0.81 (0.52, 0.94) 0.87 (0.72, 1.18) 0.562
IgA/(g/L), $\bar{x}±s$ 2.79±1.74 1.91±1.12 0.092
C3/(g/L), $\bar{x}±s$ 0.90±0.21 0.86±0.20 0.639
C4/(g/L), $\bar{x}±s$ 0.21±0.07 0.19±0.08 0.491

表6

NK细胞与临床实验室指标之间的关系"

Reduction group (n=15) Normal group (n=17) P
Age/years, $\bar{x}±s$ 53.00±14.05 48.41±12.23 0.349
Women, n(%) 15 (100) 16 (94.12) 1.000
Disease duration/years, M(P25, P75) 6.5 (1, 28) 5 (0.5, 20) 0.455
Raynaud’s phenomenon, n(%) 13 (86.67) 13 (82.35) 0.659
Diffuse cutaneous changes, n(%) 12 (80) 13 (82.35) 1.000
fingertip ulcer, n(%) 6 (40) 1 (5.88) 0.033
Pulmonary interstitial fibrosis, n(%) 11 (73.33) 12 (70.59) 1.000
ANA, n(%) 14 (93.33) 15 (88.24) 1.000
Scl-70, n(%) 5 (33.33) 6 (35.29) 1.000
ESR/(mm/h), M(P25, P75) 23.00 (10.5, 40.00) 10.00 (7.50, 18.00) 0.069
CRP/(mg/L), M(P25, P75) 5.83 (0.97, 12.12) 2.57 (0.55, 3.86) 0.242
IgG/(g/L), M(P25, P75) 11.70 (9.25, 15.60) 11.70 (9.80, 15.70) 0.655
IgM/(g/L), M(P25, P75) 0.77 (0.52, 0.94) 0.93 (0.76, 1.39) 0.049
IgA/(g/L), $\bar{x}±s$ 2.43±1.53 1.97±1.23 0.348
C3/(g/L), $\bar{x}±s$ 0.85±0.24 0.90±0.16 0.548
C4/(g/L), $\bar{x}±s$ 0.21±0.09 0.18±0.06 0.365

表7

T淋巴细胞亚群、B细胞及NK细胞数量与ESR、CRP、IgA、IgG、IgM、C3、C4之间的相关性"

Items ESR CRP IgA IgG IgM C3 C4
r P r P r P r P r P r P r P
T cells -0.455 0.009 -0.292 0.104 0.112 0.541 -0.079 0.669 -0.024 0.898 0.317 0.077 -0.022 0.903
CD4+T cells -0.416 0.018 -0.235 0.195 0.112 0.541 -0.182 0.381 -0.142 0.437 0.301 0.095 -0.008 0.964
CD8+T cells -0.430 0.014 -0.325 0.070 0.021 0.909 0.030 0.869 0.148 0.418 0.290 0.107 -0.021 0.911
B cells -0.366 0.039 -0.218 0.231 0.051 0.782 0.209 0.251 0.281 0.120 0.138 0.452 -0.289 0.108
NK cells -0.196 0.283 -0.093 0.363 0.043 0.817 0.161 0.378 0.338 0.059 0.162 0.376 -0.069 0.708
[1] Denton CP, Khanna D. Systemic sclerosis [J]. Lancet, 2017, 390(10103):1685-1699.
doi: 10.1016/S0140-6736(17)30933-9
[2] Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database [J]. Ann Rheum Dis, 2010, 69(10):1809-1815.
doi: 10.1136/ard.2009.114264
[3] van den Hoogen F, Khanna D, Fransen J, et al. Classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative [J]. Ann Rheum Dis, 2013, 72(11):1747-1755.
doi: 10.1136/annrheumdis-2013-204424 pmid: 24092682
[4] Bossini-Castillo L, Martin JE, Broen J, et al. Confirmation of TNIP1 but not RHOB and PSORSICI as systemic sclerosis risk factors in a large independent replication study [J]. Ann Rheum Dis, 2013, 72(4):602-607.
doi: 10.1136/annrheumdis-2012-201888 pmid: 22896740
[5] Marou E, Liaskos C, Efthymiou G, et al. Increased immunoreactivity against human cytomegalovirus UL83 in systemic sclerosis [J]. Clin Exp Rheumatol, 2017, 35(Suppl 106):31-34.
[6] Marie I, Gehanno JF, Bubenheim M, et al. Systemic sclerosis and exposure to heavy metals: A case control study of 100 patiens and 300 controls [J]. Autoimmun Rev, 2017, 16(3):223-230.
doi: S1568-9972(17)30014-9 pmid: 28137480
[7] Borghini A, Poscia A, Bosello S, et al. Environmental pollution by benzene and PM10 and clinical manifestation of systemic sclerosis:A correlation study [J]. Int J Environ Res Public Health, 2017, 14(11):1297.
doi: 10.3390/ijerph14111297
[8] Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer [J]. Science, 2014, 343(6167):152-157.
doi: 10.1126/science.1246886
[9] Cipriani P, Marrelli A, Liakouli V, et al. Cellular players in angiogenesis during the course of systemic sclerosis [J]. Autoimmu Rev, 2011, 10(10):641-646.
doi: 10.1016/j.autrev.2011.04.016
[10] Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR scleroderma trials and research group database [J]. Ann Rheum Dis, 2007, 66(6):754-763.
pmid: 17234652
[11] Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: Evidence that systemic sclerosis is a vascular disease [J]. Arthritis Rheum, 2013, 65(8):1953-1962.
doi: 10.1002/art.37988
[12] Liu M, Wu W, Sun X, et al. New insights into CD4+ T cell abnormalities in systemic sclerosis [J]. Cytokine Growth Factor Rev, 2016, 28:31-36.
doi: 10.1016/j.cytogfr.2015.12.002
[13] Yang XQ, Yang J, Xing XJ, et al. Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction [J]. Arthritis Res Ther, 2014, 16(1):R4.
doi: 10.1186/ar4430
[14] Yoshizaki A, Yanaba K, Iwata Y, et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model [J]. Immunology, 2010, 185(4):2502-2515.
[15] Bogoch ER, Gross DK. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations [J]. Rheumatology, 2005, 32(4):642-648.
doi: 10.1093/rheumatology/32.7.642
[16] Sakkas LI, Boqdanos DP. Systemic sclerosis: new evidence reenforces the role of B cells [J]. Autoimmu Rev, 2016, 15(2):155-161.
doi: 10.1016/j.autrev.2015.10.005
[17] Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis [J]. Immunol Lett, 2018, 195:76-82.
doi: S0165-2478(17)30430-3 pmid: 29307688
[18] Wang MH, Chandra M. B-cells in systemic sclerosis: Emerging evidence from genetics to phenotypes [J]. Curr Opin Rheumatol, 2015, 27(6):537-541.
doi: 10.1097/BOR.0000000000000215
[19] Dumoitier N, Chaigne B, Régent A, et al. Scleroderma peripheral B lymphocytes secrete interleukin-6 and transforming growth factor β and activate fibroblasts [J]. Arthritis Rheumatol, 2017, 69(5):1078-1089.
doi: 10.1002/art.v69.5
[20] Katz P, Mitchell SR, Cupps TR, et al. Suppression of B cell responses by natural killer cells is mediated through direct effects on T cells [J]. Cell Immunol, 1989, 119(1):130-142.
pmid: 2784076
[21] Fullard N, O’Reilly S. Role of innate immune system in systemic sclerosis [J]. Semin Immunopathol, 2015, 37(5):511-517.
doi: 10.1007/s00281-015-0503-7 pmid: 26159672
[22] Cossu M, van Bon L, Nierkens S, et al. The magnitude of cytokine production by stimulated CD56+ cells is associated with early stages of systemic sclerosis [J]. Clin Immunol, 2016, 173:76-80.
doi: 10.1016/j.clim.2016.09.004
[1] 田佳宜,张霞,程功,刘庆红,王世阳,何菁. 系统性红斑狼疮患者血清白细胞介素-2受体α水平及其临床意义[J]. 北京大学学报（医学版）, 2021, 53(6): 1083-1087.
[2] 赵静,孙峰,李云,赵晓珍,徐丹,李英妮,李玉慧,孙晓麟. 抗α-1C微管蛋白抗体在系统性硬化症中的表达及临床意义[J]. 北京大学学报（医学版）, 2020, 52(6): 1009-1013.
[3] 朱红林,杜倩,谌威霖,左晓霞,李全贞,刘思佳. 系统性硬化症血清细胞因子表达谱变化及调控机制[J]. 北京大学学报（医学版）, 2019, 51(4): 716-722.
[4] 肖榆冰,郭慕瑶,左晓霞. 免疫代谢与系统性红斑狼疮[J]. 北京大学学报（医学版）, 2018, 50(6): 1120-1124.
[5] 周建华，王地，王焕瑞，侯晓利，郁卫东，许克新，胡浩. γδT细胞对膀胱癌细胞的细胞毒活性及MICA/B蛋白在膀胱癌中的表达[J]. 北京大学学报(医学版), 2018, 50(4): 595-601.
[6] 刘静维, 卢戌, 杨照敏, 邓丽娟, 杨林. 负载NY-ESO-1多肽的树突状细胞激发特异性细胞毒性T淋巴细胞反应[J]. 北京大学学报(医学版), 2017, 49(5): 840-846.
[7] 刘恩阳, 刘静芳, 邵文威, 肖琳, 李国辉, 昌晓红, 邱晓彦. 肿瘤来源的IgG抑制脐带血中T细胞的增殖[J]. 北京大学学报(医学版), 2017, 49(5): 824-828.
[8] 陈玮, 胡凡磊, 刘洪江, 徐丽玲, 李英妮, 栗占国. 类风湿关节炎患者髓系来源的抑制细胞促进自身B细胞增殖[J]. 北京大学学报(医学版), 2017, 49(5): 819-823.
[9] 陈晓梅，李静，张晓盈，金月波，余迪，孙晓麟，武丽君，何菁，栗占国. 不同亚型的滤泡辅助性T淋巴细胞在类风湿关节炎中的临床意义[J]. 北京大学学报(医学版), 2016, 48(6): 958-963.
[10] 安乐美，李娟，季兰岚，李光韬，张卓莉. 类风湿关节炎患者外周血滤泡辅助性T细胞水平检测[J]. 北京大学学报(医学版), 2016, 48(6): 951-957.
[11] 石连杰，李建红，胡凡磊，李敏，张杰，李江涛，栗占国. 趋化因子配体19在类风湿关节炎患者血清中的表达及临床意义[J]. 北京大学学报(医学版), 2016, 48(4): 667-671.
[12] 孙佳鹏，卢新天，赵卫红，华瑛. 自身免疫性淋巴细胞增生综合征1例并文献复习[J]. 北京大学学报(医学版), 2015, 47(6): 1022-1027.
[13] 伍刚，彭佑铭，徐道亮，刘昌华. 腭扁桃体及外周血中记忆B细胞在IgA肾病临床进展中的异常表达[J]. 北京大学学报(医学版), 2015, 47(5): 749-753.
[14] 王微*, 遆红娟, 农琳, 张爽, 张莹, 李挺. 儿童系统性EB病毒阳性T细胞淋巴增殖性疾病临床病理学分析[J]. 北京大学学报（医学版）, 2012, 44(4): 594-598.
[15] 雷玲 , 钟小宁, 赵铖, 米存东, 李佳荃, 曾晶晶. Th17细胞及相关细胞因子在系统性硬化病小鼠模型中的表达及意义[J]. 北京大学学报（医学版）, 2012, 44(2): 259-264.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 田增民, 陈涛, Nanbert ZHONG, 李志超, 尹丰, 刘爽. 神经干细胞移植治疗遗传性小脑萎缩的临床研究（英文稿）[J]. 北京大学学报（医学版）, 2009, 41(4): 456 -458 .
[2] 郭岩, 谢铮. 用一代人时间弥合差距——健康社会决定因素理论及其国际经验[J]. 北京大学学报（医学版）, 2009, 41(2): 125 -128 .
[3] 成刚, 钱振华, 胡军. 艾滋病项目自愿咨询检测的技术效率分析[J]. 北京大学学报（医学版）, 2009, 41(2): 135 -140 .
[4] 卢恬, 朱晓辉, 柳世庆, 郑杰, 邱晓彦. 白细胞介素2促进宫颈癌细胞系HeLaS3免疫球蛋白G的表达[J]. 北京大学学报（医学版）, 2009, 41(2): 158 -161 .
[5] 袁惠燕, 张苑, 范田园. 离子交换型栓塞微球及其载平阳霉素的制备与性质研究[J]. 北京大学学报（医学版）, 2009, 41(2): 217 -220 .
[6] 徐莉, 孟焕新, 张立, 陈智滨, 冯向辉, 释栋. 侵袭性牙周炎患者血清中抗牙龈卟啉单胞菌的IgG抗体水平的研究[J]. 北京大学学报（医学版）, 2009, 41(1): 52 -55 .
[7] 董稳, 刘瑞昌, 刘克英, 关明, 杨旭东. 氯诺昔康和舒芬太尼用于颌面外科术后自控静脉镇痛的比较[J]. 北京大学学报（医学版）, 2009, 41(1): 109 -111 .
[8] 祁琨, 邓芙蓉, 郭新彪. 纳米二氧化钛颗粒对人肺成纤维细胞缝隙连接通讯的影响[J]. 北京大学学报（医学版）, 2009, 41(3): 297 -301 .
[9] Jian-wei GU, Emily YOUNG, Zhi-jun PAN, Kevan B. TUCKER, Megan SHPARAGO, Min HUANG, Amelia Purser BAILEY. SD大鼠长期高盐饮食可导致其高血压并改变肾细胞因子基因表达谱[J]. 北京大学学报（医学版）, 2009, 41(5): 505 -515 .
[10] 李宏亮*, 安卫红*, 赵扬玉, 朱曦. 妊娠合并高脂血症性胰腺炎行血液净化治疗1例[J]. 北京大学学报（医学版）, 2009, 41(5): 599 -601 .
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部